Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  
Google
Web www.equitybulls.com
Stock Report

| More

Cyprium Therapeutics and Sentynl Therapeutics sign Development and Asset Purchase Agreement

Posted On: 2021-02-24 08:14:00 (Time Zone: Arizona, USA)


Cyprium Therapeutics, Inc. ("Cyprium"), a Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress") partner company, and Sentynl Therapeutics, Inc. ("Sentynl"), a U.S.-based specialty pharmaceutical company owned by the Zydus Group, today announced the execution of an asset purchase agreement to commit development funding for and acquire Cyprium's proprietary rights to CUTX-101, its Copper Histidinate product candidate for the treatment of Menkes disease. Under the terms of the agreement, Sentynl will make an upfront cash payment to Cyprium, provide additional cash payments upon the achievement of certain regulatory milestones, and pay royalties and commercial milestone payments based on the net sales of CUTX-101. Cyprium will retain development responsibility of CUTX-101 through approval of the New Drug Application ("NDA") by the U.S. Food and Drug Administration ("FDA"), and Sentynl will be responsible for commercialization of CUTX-101 as well as progressing newborn screening activities. Continued development of CUTX-101 will be overseen by a Joint Steering Committee consisting of representatives from Cyprium and Sentynl.

"We are very pleased to partner with Sentynl to potentially expedite the development and commercialization of CUTX-101. The drug has demonstrated a compelling safety and efficacy profile in topline analysis for the treatment of Menkes disease. We look forward to working with Sentynl to begin the rolling submission of the NDA to the FDA this year. If approved, CUTX-101 will provide a major breakthrough and fill a significant unmet need for children suffering from this rare, fatal pediatric disease," said Lung S. Yam, M.D., Ph.D., President and Chief Executive Officer of Cyprium.

Matt Heck, Co-founder, President & Chief Executive Officer of Sentynl, commented, "Our mission, at the Zydus Group, has been to provide healthcare professionals with access to innovative treatment solutions that enable them to meet the needs of individual patients. We are excited to collaborate with Cyprium in order to broaden our pediatric rare disease portfolio and commercialize CUTX-101, a potentially transformative product, for children with Menkes disease, an unmet healthcare need."

Fortress' Chairman, President and Chief Executive Officer, Lindsay A. Rosenwald, M.D., added, "This transaction with Sentynl further validates the Fortress business model of identifying and developing promising treatments for patients, while pursuing partnership opportunities that potentially maximize shareholder value. We are thrilled with the progress Cyprium has made developing this treatment for Menkes disease and look forward to working with Sentynl to make CUTX-101 available to patients."

Under the agreement, Cyprium is eligible to receive up to $20 million in upfront development and regulatory cash milestones through NDA approval, as well as potential sales milestones. Royalties on CUTX-101 net sales ranging from the mid-single digits up to the mid-twenties are also payable. Cyprium will retain 100% ownership over any FDA priority review voucher that may be issued at NDA approval for CUTX-101.

Torreya Partners advised Cyprium on this transaction.

Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.432.35 as compared to the previous close of Rs. 430.4. The total number of shares traded during the day was 290898 in over 6650 trades.

The stock hit an intraday high of Rs. 438 and intraday low of 412.8. The net turnover during the day was Rs. 124819515.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com


Other Headlines:

Indiabulls Housing Finance Ltd. ties up with HDFC Ltd. for Co-Lending Partnership

Tejas Networks Ltd Q4FY21 consolidated PAT soars to Rs. 33.55 crore

ICICI Securities Ltd reports Rs. 329.47 crore consolidated PAT in Q4FY21

Phillips Carbon Black Ltd posts consolidated PAT of Rs. 127.73 crores in Q4FY21

Wonderla announces closure of Bangalore Park till May 4

Hero MotoCorp and Gogoro® Inc announce strategic partnership

Three ONGC employees abducted by armed miscreants in Sivasagar, Assam

Indigo Paints Limited board to approve Q3, Q4, FY21 results on May 14, 2021

Coromandel International Ltd board to announce Q4, FY21 results on April 29, 2021

Hathway Cable & Datacom Ltd board to consider FY21 results on April 28, 2021

Seshasayee Paper and Boards Ltd board to approve FY21 results on May 8, 2021

Rossari Biotech Limited allots 30,12,046 Equity Shares at Rs. 996 per share

Ajanta Pharma Ltd board to consider Q4, FY21 results on April 30, 2021

Maruti Suzuki India Ltd introduces New version of RPAS System in Eeco Cargo Variants

KEC International wins New Orders of Rs. 1,245 crores

MTAR Technologies Limited: Ratings upgraded, outlook revised to Positive

ACC unveiled a new range of innovative and sustainable products during COVID-19

Supreme Industries Ltd board to approve dividend, FY21 results on May 3, 2021

Mastek Ltd board to consider final dividend, FY21 results on April 28, 2021

Enkei Wheels (India) Ltd board to announce quarterly results on April 28, 2021

ICICI Securities board recommends final dividend of Rs. 13.50

TCS Named a Leader in the 2021 Gartner Magic Quadrant for Managed Workplace Services, Asia Pacific

Shri Bajrang Alliance Limited's Agro Division now certified under Food Safety Management System

5Paisa Capital Ltd Q4FY21 consolidated net profit surges to Rs. 5.85 crore

Accelya Solutions India Ltd board to consider Q3FY21 results on April 30, 2021

Van Heusen launches new sub-brand 'Denim Labs'

Shriram City Union Finance Ltd board to approve final dividend, FY21 results on April 30, 2021

Larsen & Toubro Infotech Ltd board to conider Q4, FY21 results, dividend on May 4, 2021

Cipla Ltd board to consider Q4, FY21 results, dividend on May 14, 2021

Tata Steel Long Products Ltd Board approves dividend of Rs. 5

Swaraj Engines Limited announces Q4FY21 results

AstraZeneca Pharma India Limited launches Fasenra™

Hero MotoCorp to undertake temporary suspension of manufacturing operations as precautionary measure

Salasar Techno Engineering Ltd receives orders worth Rs. 47.70 crore

Supreme Petrochem Ltd Board to consider FY21 results & Dividend on April 30, 2021

IRDAI imposes penalty of Rs. 25 lacs on SBI General Insurance Company Limited

Tata Steel Long Products Ltd Q4FY21 consolidated PAT soars to Rs. 339.86 crore

Network18 Media & Investments Ltd reports Rs. 39.13 crore consolidated PAT in Q4FY21

Quick Heal Technologies Ltd fixes May 3, 2021 as record date for Buy Back

TV18 Broadcast Ltd reports Q4FY21 consolidated PAT of Rs. 165.88 crore

Swaraj Engines Ltd Board approves dividend of Rs. 50, special dividend of Rs. 19

Blue Dart Express Ltd board to consider Q4, FY21 results, dividend on May 5, 2021

Swaraj Engines Ltd Q4FY21 PAT surges to Rs. 32.56 crore

Narendra Investments Delhi Ltd Q4FY21 PAT up at Rs. 0.35 crore

Nestle India Ltd reports jump in net profit to Rs. 602.25 crore in Q1CY21

Central Bank of India board approves issue of shares at Rs. 17.11

Saregama strikes a long term music deal with Sanjay Leela Bhansali

Nestle India Ltd board declares interim dividend of Rs. 25 for CY2021

TCI Industries Limited approves issue of 107602 NCRPS

Alembic Pharmaceuticals Ltd board to consider Q4, FY21 results on March 31, 2021


Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020